ScholarIQanswers from OpenAlex & ORCID
Alan J. Korman
ResearcherPublications, citations & collaboration network
Alan J. Korman is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Alan J. Korman have?
ScholarIQindexed works
Alan J. Korman has 386 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Alan J. Korman have?
ScholarIQcitation count
Alan J. Korman has 51,710 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Alan J. Korman?
ScholarIQh-index
Alan J. Korman has an h-index of 72 in OpenAlex.
What is the i10-index of Alan J. Korman?
ScholarIQi10-index
Alan J. Korman has an i10-index of 120 in OpenAlex.
What is the ORCID of Alan J. Korman?
ScholarIQorcid
The ORCID for Alan J. Korman is on the source record.
What is the OpenAlex record for Alan J. Korman?
ScholarIQopenalex
The OpenAlex for Alan J. Korman is on the source record.
What are the most-cited papers on Alan J. Korman?
ScholarIQmost cited works
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
Suzanne L. Topalian, F. Stephen Hodi, Julie R. Brahmer, Scott Gettinger, David C. Smith, David F. McDermott, John D. Powderly, Richard D. Carvajal, Jeffrey A. Sosman, Michael B. Atkins, Philip D. Leming, David R. Spigel, Scott Antonia, Leora Horn, Charles G. Drake, Drew M. Pardoll, Lieping Chen, William H. Sharfman, Robert A. Anders, Janis M. Taube, Tracee L. McMiller, Haiying Xu, Alan J. Korman, Maria Jure–Kunkel, Shruti Agrawal, D. G. McDonald, Georgia Kollia, Ashok Gupta, Jon M. Wigginton, Mario Sznol
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
Julie R. Brahmer, Scott S. Tykodi, Laura Q.M. Chow, Wen-Jen Hwu, Suzanne L. Topalian, Patrick Hwu, Charles G. Drake, Luis H. Camacho, John Kauh, Kunle Odunsi, Henry C. Pitot, Omid Hamid, Shailender Bhatia, Renato Martins, Keith D. Eaton, Shuming Chen, Theresa M. Salay, Suresh Alaparthy, Joseph F. Grosso, Alan J. Korman, Susan Parker, Shruti Agrawal, S. Goldberg, Drew M. Pardoll, Ashok Gupta, Jon M. Wigginton
Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates
Julie R. Brahmer, Charles G. Drake, Ira Wollner, John D. Powderly, Joel Picus, William H. Sharfman, Elizabeth Stankevich, Alice Pons, Theresa M. Salay, Tracee L. McMiller, Marta M. Gilson, Changyu Wang, Mark Selby, Janis M. Taube, Robert A. Anders, Lieping Chen, Alan J. Korman, Drew M. Pardoll, Israel Lowy, Suzanne L. Topalian
Immune Inhibitory Molecules LAG-3 and PD-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune Escape
Seng‐Ryong Woo, Meghan E. Turnis, Monica V. Goldberg, Jaishree Bankoti, Mark Selby, Christopher J. Nirschl, Matthew L. Bettini, David M. Gravano, Peter Vogel, Chih Long Liu, Stephanie Tangsombatvisit, Joseph F. Grosso, George J. Netto, Matthew P. Smeltzer, Alcides Chaux, Paul J. Utz, Creg J. Workman, Drew M. Pardoll, Alan J. Korman, Charles G. Drake, Dario A.A. Vignali
Elective Nodal Irradiation Attenuates the Combinatorial Efficacy of Stereotactic Radiation Therapy and Immunotherapy
Ariel E. Marciscano, Ali Ghasemzadeh, Thomas R. Nirschl, Debebe Theodros, Christina M. Kochel, Brian J. Francica, Yuki Muroyama, Robert A. Anders, Andrew B. Sharabi, Esteban Velarde, Wendy Mao, Kunal Chaudhary, Matthew G. Chaimowitz, John Wong, Mark Selby, Kent Thudium, Alan J. Korman, David Ulmert, Daniel L.J. Thorek, Theodore L. DeWeese, Charles G. Drake